Recommended Free CME and Other Educational Activities in Hematology

Moving the Needle: Adopting New Evidence Into the Lower-Risk Myelodysplastic Syndrome Treatment Paradigm

Moving the Needle: Adopting New Evidence Into the Lower-Risk Myelodysplastic Syndrome Treatment Paradigm

While the frontline treatment landscape expands for lower-risk myelodysplastic syndrome (LR-MDS), providers are faced with new opportunities and challenges to individualizing care. …
Free Live Webinar1.0 CME/CEJun 18, 2024
Access
Expert Insights and System-Based Care Trends in Early-Stage NSCLC and Melanoma, Metastatic Bladder Cancer, and Relapsed/Refractory Follicular Lymphoma
Coming on Apr 20, 2024

Expert Insights and System-Based Care Trends in Early-Stage NSCLC and Melanoma, Metastatic Bladder Cancer, and Relapsed/Refractory Follicular Lymphoma

JW Marriott Indianapolis - CLICK HERE for Venue InformationAdvances in oncology are transforming the therapeutic landscape at a rapid pace, generating urgent needs to update clinical protocols and workflows based on emerging clinical data. On April 20th, join leading experts live in-person in Indianapolis or via livestream for this…
Free Live Meeting4.0 CME/CEApr 20, 2024
Register
Navigating Transitions to Adult Care for Sickle Cell Disease: A Toolkit for Healthcare Providers and Their Patients

Navigating Transitions to Adult Care for Sickle Cell Disease: A Toolkit for Healthcare Providers and Their Patients

One of the primary difficulties experienced by adolescents and young adults with sickle cell disease (SCD) is the transition from pediatric to adult health care services, as patients often have limited guidance and clinical manifestations from their disease that prevent them from collating the comprehensive, multi-specialty adult care…
Free Patient Toolkit1.0 CME/CE
Access
Positioning CAR T-Cell Therapy in the CLL Treatment Landscape

Positioning CAR T-Cell Therapy in the CLL Treatment Landscape

Are you ready to enhance your understanding and expertise in the evolving field of chimeric antigen receptor (CAR) T-cell therapy for chronic lymphocytic leukemia (CLL)? Join us for an interactive exploration of the latest clinical evidence and strategies aimed at effectively positioning CAR T-cell therapy in CLL care. …
Free AdaptiveMed1.0 CME/CE
Access
Beyond Transfusions: New and Emerging Therapies for Beta Thalassemia

Beyond Transfusions: New and Emerging Therapies for Beta Thalassemia

Are you ready for the shifting treatment paradigm for beta thalassemia? Join expert faculty as they review the latest clinical data for novel therapies for beta thalassemia and put your knowledge to the test with integrated polling questions on emerging evidence. …
Free Online Activity0.5 CME/CE
Access
Empowering Patients in Their Beta Thalassemia Care: Strategies for Effective Transitions of Care and Shared Decision-Making

Empowering Patients in Their Beta Thalassemia Care: Strategies for Effective Transitions of Care and Shared Decision-Making

Among the top challenges faced by adolescents and young adults with beta thalassemia is the transition from pediatric to adult care services. As beta thalassemia patients struggle to adhere to treatment plans that reduce transfusion requirements, there is an unprecedented need to optimize transitions of care (ToC) to ensure that…
Free Online Activity0.25 CME/CE
Access
Supporting Patients in Navigating Novel Therapies for Multiple Myeloma Treatment

Supporting Patients in Navigating Novel Therapies for Multiple Myeloma Treatment

Advancements in the treatment and management of multiple myeloma (MM) have led to improved outcomes for patients with this disease, but have also generated challenges for both patients and providers in navigating MM care decisions. …
Free Online Activity1.0 CME/CE
Access
Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

Recent advances in the risk stratification, treatment, and management of myelodysplastic syndrome (MDS) offer new opportunities to personalize treatment and improve patient outcomes. As we enter this new era of MDS care, are you ready to integrate these advances into individualized treatment plans for MDS patients? …
Free Online Activity1.5 CME/CEMOC
Access
Advancing cTTP Care Through Integration of the Latest Clinical Evidence

Advancing cTTP Care Through Integration of the Latest Clinical Evidence

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare and life-threatening hematologic disorder. Recent advances in the diagnosis, treatment, and management of cTTP offer new opportunities to optimize treatment and improve patient outcomes. …
Free Online Activity1.5 CME/CEMOC
Access
Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-Cell Lymphoma

Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-Cell Lymphoma

Tune in to hear expert faculty in diffuse large B-cell lymphoma (DLBCL) take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of antibody-based therapies into treatment plans during this recording of a presentation from the 65th American Society of Hematology (ASH) Annual Meeting…
Free Online Activity1.5 CME/CEMOC
Access
Elevating Care Coordination for Timely Management of Follicular Lymphoma

Elevating Care Coordination for Timely Management of Follicular Lymphoma

Tune in to this webcast, featuring an in-depth look at the latest clinical evidence for follicular lymphoma (FL) treatment and management with a focus on care in federal, public, and government healthcare settings. …
Free Online Activity0.5 CME/CEMOC
Access
Accelerating Adoption of Novel Therapies for Optimal Diffuse Large B-Cell Lymphoma Care

Accelerating Adoption of Novel Therapies for Optimal Diffuse Large B-Cell Lymphoma Care

The treatment paradigm for diffuse large B-cell lymphoma (DLBCL) is rapidly evolving, requiring clinicians to stay up to date with recent immunotherapy approvals and new indications for optimal patient outcomes. Tune in for an in-depth look at the latest guidelines and clinical evidence in DLBCL treatment and management and hear experts…
Free Online Activity1.0 CME/CEMOC
Access
Advancing Collaborative Multiple Myeloma Care Coordination Among Oncology Centers

Advancing Collaborative Multiple Myeloma Care Coordination Among Oncology Centers

Providers caring for patients with multiple myeloma (MM) face unique challenges as they sequence multiple lines of therapy and coordinate care between community oncology clinics and large academic centers. …
Free Online Activity1.0 CME/CE
Access
Expanding Access to Novel Treatment Approaches for Multiple Myeloma

Expanding Access to Novel Treatment Approaches for Multiple Myeloma

The treatment landscape for multiple myeloma (MM) is rapidly evolving, leaving clinicians with the task of creating individualized treatment plans based on various patient-, disease-, and treatment-related factors. …
Free Online Activity1.0 CME/CEMOC
Access
Improving Access to Quality Evidence-Based Care for Acute Myeloid Leukemia

Improving Access to Quality Evidence-Based Care for Acute Myeloid Leukemia

With the approval of several targeted therapies for acute myeloid leukemia (AML), timely access to and accurate interpretation of molecular and genetic testing is critical for individualized treatment plans.Tune in to hear experts discuss the role of molecular and prognostic factors that guide AML treatment decisions and the latest…
Free Online Activity1.0 CME/CEMOC
Access
Navigating the Evolving Treatment Paradigm for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Navigating the Evolving Treatment Paradigm for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

From the integration of refined risk stratification schemas to the magnitude of emerging data for novel therapeutic agents, the clinical advances for the management of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) hold the potential to transform patient outcomes. Catch all of the latest evidence in this webcast,…
Free Online Activity1.0 CME/CEMOC
Access
Watch and Wait or Initiate: Providing Timely Access to Novel Therapies for Chronic Lymphocytic Leukemia

Watch and Wait or Initiate: Providing Timely Access to Novel Therapies for Chronic Lymphocytic Leukemia

The decision to watch and wait or begin treatment in chronic lymphocytic leukemia (CLL) is complex; yet while clinicians struggle to navigate the latest clinical evidence, optimal patient outcomes are foremost impeded by barriers to timely access to care. Tune in for a deep dive into the latest clinical data for new and emerging…
Free Online Activity0.5 CME/CEMOC
Access
Uncovering the Burden of Anemia in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Uncovering the Burden of Anemia in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Anemia is a hallmark of patients with lower-risk myelodysplastic syndromes (MDS), myelofibrosis (MF), and beta thalassemia, with severe anemia often requiring regular blood transfusions that take a toll on patient quality of life. In the first video in our Anemia Management Accelerator Hub, leading hematology/oncology experts assess and…
Free Online Activity0.25 CME/CE
Access
Navigating Anemia Evaluation and Diagnostic Best Practices for Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Navigating Anemia Evaluation and Diagnostic Best Practices for Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Obtaining a prompt and accurate explanation for anemia is critical for treatment decision-making. In the second video in our Anemia Management Accelerator Hub, expert faculty delve into the best practices for diagnosing the underlying cause of anemia and shed light on the diversity of anemia presentation in hematologic disorders,…
Free Online Activity0.25 CME/CE
Access
Applying the Latest Evidence for Anemia Management in Patients With Lower-Risk Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Applying the Latest Evidence for Anemia Management in Patients With Lower-Risk Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia

Novel and emerging treatments are reducing transfusion requirements for patients with anemia due to lower-risk myelodysplastic syndrome (MDS), myelofibrosis (MF), and beta thalassemia. However, keeping up with the latest clinical evidence for current and emerging therapies remains a challenge. Join us for the third video in our Anemia…
Free Online Activity0.25 CME/CE
Access
Optimizing Anemia Management in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia Through Shared Decision-Making

Optimizing Anemia Management in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia Through Shared Decision-Making

Patients with anemia due to an underlying diagnosis of myelodysplastic syndrome (MDS), myelofibrosis (MF), and beta thalassemia face diverse challenges, and communication of their unique goals and preferences is critical for deciding upon individualized anemia management plans.In the final video in our Anemia Management Accelerator Hub,…
Free Online Activity0.25 CME/CE
Access